TBC1D30

Across TCGA pan-cancer cohorts, TBC1D30 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of TBC1D30’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where TBC1D30 RNA is repressed in tumor relative to normal tissue. In most cancer types TBC1D30 is over-expressed in tumor, although a few such as KIRC and THCA show the opposite, repressed pattern.

KIRC, COAD, and THCA are the cancer types where TBC1D30 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TBC1D30 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−0.870	<.001	12	view →
COAD	Female	II,III,IV	+1.193	<.001	11	view →
THCA	Male	III,IV	−0.927	<.001	10	view →
LIHC	All	II,III,IV	+0.753	<.001	9	view →
STAD	Male	All	+1.110	<.001	8	view →
HNSC	Male	All	+0.853	<.001	8	view →
BRCA	All	III,IV	+1.075	<.001	6	view →
BLCA	Female	III,IV	+0.965	.010	6	view →
LUAD	Male	All	+0.644	<.001	6	view →
LUSC	All	All	−0.490	<.001	5	view →
UCEC	All	All	+0.454	.007	4	view →
CHOL	All	All	+2.252	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

TBC1D30–KIRC

Open the KIRC breakdown →